New therapeutic perspectives in CCDC6 deficient lung cancer cells-Reference-Cited by-同舟云学术

New therapeutic perspectives in CCDC6 deficient lung cancer cells

Published:2014-10-24 Issue:9 Volume:136 Page:2146-2157
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Morra Francesco¹²,Luise Chiara¹,Visconti Roberta¹,Staibano Stefania³,Merolla Francesco³,Ilardi Gennaro³,Guggino Gianluca⁴,Paladino Simona²,Sarnataro Daniela²⁵,Franco Renato⁶,Monaco Roberto⁷,Zitomarino Federica⁶,Pacelli Roberto³,Monaco Guglielmo⁴,Rocco Gaetano⁸,Cerrato Aniello¹,Linardopoulos Spiros⁹,Muller Mark T.¹⁰,Celetti Angela¹

Affiliation:

1. Istituto per l'Endocrinologia e l'Oncologia Sperimentale “Gaetano Salvatore”, CNR; Napoli Italy

2. Dipartimento di Medicina Molecolare e Biotecnologie Mediche; Università Federico II; Napoli Italy

3. Dipartimento di Scienze Biomediche Avanzate; Università Federico II; Napoli Italy

4. UOC Chirurgia Toracica; Azienda Ospedaliera di Rilievo Nazionale “A.Cardarelli”; Napoli Italy

5. CEINGE-Biotecnologie Avanzate; Napoli Italy

6. UOC Anatomia Patologica e Citopatologia; , ISNT “Fondazione G. Pascale”; Napoli Italy

7. UOC Anatomia Patologica; Azienda Ospedaliera di Rilievo Nazionale “A.Cardarelli”; Napoli Italy

8. UOC Chirurgia Toracica; ISNT “Fondazione G. Pascale”; Napoli Italy

9. The Breakthrough Breast Cancer Research Centre; The Institute of Cancer Research; 237 Fulham Road, London SW3 6JB United Kingdom

10. Department of Molecular Biology and Microbiology; College of Medicine, University of Central Florida; Orlando FL

Funder

AIRC

MIUR

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference50 articles.

1. Cancer statistics 2009;Jemal;CA Cancer J Clin,2009

2. Biomarker studies: a call for a comprehensive biomarker study registry;Andre;Nat Rev Clin Oncol,2011

3. DNA repair dysregulation from cancer driver to therapeutic target;Curtin;Nat Rev Cancer,2012

4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

5. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: up dated results from a phase 1 study;Camidge;Lancet Oncol,2012

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Function of TRPC1 in modulating hepatocellular carcinoma progression;Medical Oncology;2023-02-16

2. Targeting Oncogenic Driver Mutations in Lung Cancer;El in Molecular Onco;2023-01-12

3. The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma;Journal of Experimental & Clinical Cancer Research;2022-08-13

4. High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma;Journal of Cancer;2022

5. The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis;Heliyon;2021-11